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Introduction {#sec1}
============

One of the most interesting and least understood aspects of energy balance modulation is gender dimorphism. Although some common mechanisms control energy balance in both males and females, elevated levels of ovarian steroids deeply affect metabolic networks in females ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]). For example, diminished levels of estradiol (E2) after ovarian insufficiency of any etiology, including physiological (menopause) or surgical (ovariectomy \[OVX\]), are associated with hyperphagia, reduced energy expenditure, and weight gain ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]). E2 replacement in these conditions precludes or reverts OVX-induced obesity by reducing energy intake and elevating energy expenditure; in keeping with this, E2 replacement also prevents metabolic complications, such as glucose intolerance and diabetes. ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]). Although these beneficial effects of E2 were assumed to be mostly exerted at the peripheral level, recently gleaned data have shown that, to a large extent, they are exerted at the hypothalamus.

E2 directly acts on the CNS to modulate energy balance ([@bib16], [@bib17]). Estrogen receptors (ERs) are widely expressed throughout the brain, particularly in hypothalamic sites, such as the arcuate (ARC), ventromedial (VMH), and paraventricular (PVH) nuclei, as well as the preoptic (POA) and lateral (LHA) hypothalamic areas ([@bib52], [@bib53], [@bib59], [@bib36], [@bib32]), all having critical roles in the regulation of energy metabolism ([@bib47], [@bib48], [@bib21], [@bib20], [@bib7]). Several lines of evidence have shown that E2 exerts a nucleus-specific action in the hypothalamus to modulate energy homeostasis. Thus, while most of the effects of E2 on feeding occur in proopiomelanocortin (POMC) neurons in the ARC ([@bib64]), E2 within the VMH modulates brown adipose tissue (BAT) thermogenesis ([@bib35], [@bib64], [@bib24], [@bib25]). However, the exact molecular mechanism by which E2 exerts its actions in this nucleus remains unknown.

Current evidence has pointed to hypothalamic endoplasmic reticulum (ER) stress as a central pathophysiological mechanism leading to insulin and leptin resistance and subsequently to obesity ([@bib66], [@bib22], [@bib37], [@bib46]). It also has been shown that central ceramide-induced lipotoxicity affects energy balance ([@bib44], [@bib41], [@bib55], [@bib4], [@bib21]). In the hypothalamus, elevated ceramide concentration elicits ER stress, leading to weight gain, insulin resistance, hepatic steatosis, decreased sympathetic tone, and BAT thermogenesis ([@bib4], [@bib6]). Notably, the central action of ceramides can be reversed by decreasing hypothalamic ER stress, resulting in increased BAT thermogenesis and browning of white adipose tissue (WAT), which ultimately ameliorates obesity ([@bib4], [@bib6]). It also has been reported that peripheral E2 treatment reduces serum ceramide concentration in OVX rats ([@bib58]). However, despite this evidence, it is currently unknown (1) whether ovarian estrogens modulate hypothalamic ceramide-induced lipotoxicity, and, more importantly, (2) whether impairment of this mechanism may be the cause of obesity in conditions of estrogen deficiency. Therefore, in this study we aim to determine the importance of hypothalamic ceramides and ER stress on the central effects of E2 on energy homeostasis.

Results {#sec2}
=======

Central E2 Inhibits Hypothalamic Ceramide-Induced Lipotoxicity and ER Stress {#sec2.1}
----------------------------------------------------------------------------

OVX rats gained significantly more weight 15 days after the procedure (sham: 12.7 ± 2.54 g; OVX: 48.63 ± 2.38 g; p \< 0.001) and developed a marked hyperphagia (sham: 16.1 ± 0.42 g; OVX: 18.25 ± 0.40 g after 15 days of OVX; p \< 0.001). OVX rats showed the expected decrease in uterus weight and an increase in serum luteinizing hormone (LH) (data not shown), confirming the efficiency of the OVX procedure ([@bib24], [@bib25]). As expected, central (intracerebroventricular, ICV) E2 treatment elicited a marked decrease in body weight and feeding ([Figures 1](#fig1){ref-type="fig"}A and 1B), as well as a reduction in adiposity and lean mass ([Figure 1](#fig1){ref-type="fig"}C). As reported before ([@bib3]), central E2 administration did not affect oxygen consumption (VO~2~ 72-hr sham vehicle: 121.16 ± 2.76 mL/g lean mass; VO~2~ 72-hr OVX vehicle: 114.66 ± 3.13 mL/g lean mass; VO~2~ 72-hr OVX E2: 118.17 ± 3.1 mL/g lean mass). However, central E2 significantly augmented the energy expenditure (EE) of OVX rats ([Figure 1](#fig1){ref-type="fig"}D). In keeping with this evidence, OVX rats receiving ICV E2 showed a reduced respiratory quotient (RQ; [Figure 1](#fig1){ref-type="fig"}E), which is indicative of higher lipid oxidation, as well as an increase in body temperature and in BAT temperature ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), uncoupling protein 1 (UCP1) BAT expression ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and a reduction in the hepatic lipid content ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The selected dose of E2 was formerly demonstrated to be in the physiological range and not to leak to periphery from the cerebrospinal fluid ([@bib24], [@bib25]).Figure 1Effect of Central E2 and Myriocin on Energy Balance in OVX Rats(A--G) Body weight change (A), daily food intake (B), fat mass change (left panel) and lean mass change (right panel) (C), time course energy expenditure (EE) (left panel) and total energy expenditure change (right panel) (D), respiratory quotient (E), ceramide levels in the MBH (F), and representative western blot autoradiographic images (left panel) and MBH protein levels of UPR (right panel) (G) of sham rats or OVX rats ICV treated with vehicle or E2 (n = 7--9 animals per group).(H--O) Body weight change (H), daily food intake (I), fat mass change (left panel) and lean mass change (right panel) (J), ceramide levels in the MBH (K), representative western blot autoradiographic images (left panel) and MBH protein levels of UPR (right panel) (L), body temperature (M), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (N), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (O) of sham rats or OVX rats ICV treated with vehicle or myriocin (n = 7--16 animals per group for all the analyses, but the body weight and food intake measurements were n = 28--38).All data are expressed as mean ± SEM. ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05, 0.01, and 0.001 versus sham vehicle; \#, \#\#, and \#\#\# p \< 0.05, 0.01, and 0.001 versus OVX vehicle. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (β-actin or α-tubulin). The bands for each picture always come from the same gel, although they have been spliced for clarity.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Next, we investigated the effect of OVX and central E2 replacement on ceramide content in the mediobasal hypothalamus (MBH). We found that OVX induced a marked elevation of hypothalamic ceramide levels and that E2 ICV restored them to the levels observed in sham-operated rats ([Figure 1](#fig1){ref-type="fig"}F). Of note, in association to the rise in ceramide concentration, OVX rats showed increased hypothalamic ER stress in the MBH, as demonstrated by the augmented levels of unfolded protein response (UPR) markers, such as phosphorylated inositol-requiring enzyme (pIRE), phosphorylated PKR-like ER kinase (pPERK), phosphorylated eukaryotic initiation factor 2 alpha (peIF2α), and C/EBP homologous protein (CHOP) ([Figure 1](#fig1){ref-type="fig"}G). Again, central E2 administration reversed the increased ER stress by blunting the elevated levels of the UPR markers to the levels of those detected in the sham controls. Particularly, the hypothalamic expression of the chaperone glucose regulated protein 78 kDa (GRP78; also called binding immunoglobulin protein \[BiP\]; see below) was increased after central treatment with E2, as a cellular mechanism to reduce ER stress ([Figure 1](#fig1){ref-type="fig"}G).

Pharmacological Inhibition of Hypothalamic Ceramide Synthesis Recapitulates the Effect of Central E2 on Energy Balance through the SNS {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------

Ceramide-induced lipotoxicity has been reported to promote positive energy balance due to reduced thermogenic capacity ([@bib4], [@bib6]). Therefore, we aimed to investigate whether inhibition of ceramide synthesis in the hypothalamus of OVX rats might improve their metabolic phenotype. Chronic ICV administration of the ceramide inhibitor myriocin ([@bib44]) to OVX rats decreased body weight and adiposity independent of feeding ([Figures 1](#fig1){ref-type="fig"}H--1J). This effect was associated with normalization of ceramide and ER stress markers levels in the MBH ([Figures 1](#fig1){ref-type="fig"}K and 1L), increased body temperature ([Figure 1](#fig1){ref-type="fig"}M), elevated BAT temperature ([Figure 1](#fig1){ref-type="fig"}N) and raised UCP1 protein levels in the BAT ([Figure 1](#fig1){ref-type="fig"}O), as well as reduced hepatic lipid levels ([Figure S1](#mmc1){ref-type="supplementary-material"}E) of OVX rats. Given that central ceramides have been reported to induce a marked decrease in the activity of the sympathetic nervous system (SNS) innervating BAT ([@bib4]), we aimed to investigate whether adrenergic receptor blockade affected the central effect of ICV myriocin on BAT thermogenesis of OVX rats. The effect of central administration of myriocin was reversed (in a feeding-independent manner) by pharmacological blockade of beta 3 adrenergic receptor (β3-AR) with the specific antagonist, SR59230A ([@bib19], [@bib24], [@bib4], [@bib6], [@bib26], [@bib50]) ([Figures 2](#fig2){ref-type="fig"}A and 2B). The increase in body weight induced by SR59230A was associated with equivalent reversal of ICV myriocin-induced activation of body temperature ([Figure 2](#fig2){ref-type="fig"}C), BAT temperature ([Figure 2](#fig2){ref-type="fig"}D), and BAT UCP1 expression ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Effect of Myriocin and β3-AR Antagonism on BAT Thermogenesis in OVX Rats(A--E) Body weight change (A), daily food intake (B), body temperature (C), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (D), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (E) of OVX rats ICV treated with myriocin and subcutaneously treated with vehicle or the β3-AR antagonist SR59230A (n = 7--18 animals per group).All data are expressed as mean ± SEM. ^∗∗^ and ^∗∗∗^p \< 0.01 and 0.001 versus OVX vehicle vehicle; \#, \#\#, and \#\#\# p \< 0.05, 0.01, and 0.001 versus OVX myriocin vehicle. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (α-tubulin). The bands for each picture always come from the same gel, although they have been spliced for clarity.

Silencing of SPTLC Specifically in the VMH Ameliorates ER Stress and the Metabolic Phenotype of OVX Rats {#sec2.3}
--------------------------------------------------------------------------------------------------------

To further investigate the role of *de novo* ceramide synthesis pathway and to dissect in which hypothalamic nucleus those actions take place, we targeted serine palmitoyltransferase long chain base subunit 1 (SPTLC1). This enzyme catalyzes the limiting first step in the *de novo* synthesis of ceramides: the condensation of palmitoyl-CoA and serine, producing 3-ketosphinganine. The SPTLC is composed of two subunits (SPTLC1 and 2); both are essential for enzyme function because they constitute its catalytic core ([@bib11], [@bib65], [@bib61]). Therefore, we silenced SPTLC1 expression by using adenoviruses harboring a small hairpin RNA (shRNA) or control adenoviruses expressing green fluorescence protein (GFP) alone ([@bib61]), specifically in the VMH, a key hypothalamic nucleus modulating thermogenesis ([@bib33], [@bib5]). Infection in the VMH was assessed by visualization of GFP expression ([Figure 3](#fig3){ref-type="fig"}A) and by decreased protein levels of SPTLC1 ([Figure 3](#fig3){ref-type="fig"}B). Given that the stability of the SPTLC2 subunit is inherently dependent on the expression of SPTLC1 and both subunits associate with a 1:1 molar stoichiometry ([@bib11], [@bib61]), silencing SPTLC1 also led to an attendant reduction in the expression of SPTLC2 ([Figure 3](#fig3){ref-type="fig"}B), as expected and as previously shown ([@bib61]).Figure 3Effect of SPTLC1 Downregulation in the VMH of OVX Rats on Energy Balance(A--H) Direct fluorescence of GFP (A), representative western blot autoradiographic images (left panel) and VMH protein levels of serine palmitoyltransferase, long chain subunit 1-2 (right panel) (B), body weight change (C and E), daily food intake (D and F), and representative western blot autoradiographic images (left panel) and VMH protein levels of UPR (right panel) (G and H) of sham or OVX rats stereotaxically treated with adenoviruses encoding GFP or shSPTLC1 into the VMH (n = 7--20 animals per group).All data are expressed as mean ± SEM. ^∗^, ^∗∗^ and ^∗∗∗^p \< 0.05, 0.01, and 0.001 versus sham GFP or OVX GFP. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (β-actin). The bands for each picture always come from the same gel, although they have been spliced for clarity.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Administration of adenoviruses encoding shSPTLC1 in the VMH induced a feeding-independent weight loss in OVX rats, but not in sham rats ([Figures 3](#fig3){ref-type="fig"}C--3F). This effect was associated with a marked relief of ER stress in the VMH of OVX rats, as demonstrated by the reduced protein levels of pIRE, pPERK, peIF2α, ATF6α, and CHOP, which were also observed in sham rats, but to a lesser extent ([Figures 3](#fig3){ref-type="fig"}G--3H). In keeping with these data, injection of shSPTLC1 adenoviruses led to increased body temperature ([Figures 4](#fig4){ref-type="fig"}A and 4B), BAT temperature ([Figures 4](#fig4){ref-type="fig"}C and 4D) and UCP1 protein levels in the BAT ([Figures 4](#fig4){ref-type="fig"}E and 4F) of OVX, but not of sham, rats. These effects were associated with an improvement in the metabolic phenotype of OVX rats, as demonstrated by decreased hepatic steatosis ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Overall, these results, alongside the myriocin data, indicate that the hypothalamic and, more precisely, VMH ceramide levels mediated the central actions of E2 on BAT thermogenesis and energy balance.Figure 4Effect of SPTLC1 Downregulation in the VMH of OVX Rats on BAT Thermogenesis(A--F) Body temperature (A and B), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (C and D), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (E and F) of sham or OVX rats stereotaxically treated in the VMH with adenoviruses encoding GFP or shSPTLC1 (n = 7--20 animals per group).All data are expressed as mean ± SEM. ^∗^ and ^∗∗∗^p \< 0.05 and 0.001 versus sham GFP or OVX GFP. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (α-tubulin). The bands for each picture always come from the same gel, although they have been spliced for clarity.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Pharmacological Inhibition of Hypothalamic ER Stress Recapitulates the Effect of Central E2 on Energy Balance {#sec2.4}
-------------------------------------------------------------------------------------------------------------

Increased hypothalamic ER stress has been associated with the development of insulin and leptin resistance, leading to obesity ([@bib66], [@bib37], [@bib56], [@bib46], [@bib4], [@bib6]). Bearing in mind that hypothalamic ceramides elicit ER stress ([@bib4], [@bib6]), we aimed to investigate whether ceramide-induced ER stress may be a mechanism mediating the central actions of E2 deficiency on BAT thermogenesis and energy homeostasis. Thus, OVX rats were ICV treated with the chemical chaperone tauroursodeoxycholic acid (TUDCA) ([@bib66], [@bib37], [@bib46], [@bib13], [@bib6], [@bib43]). Central administration of this drug to OVX, but not sham, rats induced feeding-independent weight loss ([Figures 5](#fig5){ref-type="fig"}A--5D), decreased hypothalamic ER stress ([Figures 5](#fig5){ref-type="fig"}E and 5F), a trend to increase body temperature ([Figure 5](#fig5){ref-type="fig"}G), elevated BAT temperature ([Figure 5](#fig5){ref-type="fig"}H) and UCP1 protein levels in BAT ([Figure 5](#fig5){ref-type="fig"}I). Of note, none of the metabolic changes were found in sham rats ([Figures 5](#fig5){ref-type="fig"}G--5I), which is in line with the fact that they did not show elevated ER stress ([Figures 1](#fig1){ref-type="fig"}G and 1L). Furthermore, the central injection of TUDCA reduced the hepatic lipid content of OVX rats but had no effects in sham rats ([Figure S3](#mmc1){ref-type="supplementary-material"}A).Figure 5Effect of Central TUDCA on Energy Balance in OVX Rats(A--I) Body weight change (A and C), daily food intake (B and D), representative western blot autoradiographic images (left panel) and MBH protein levels of UPR (right panel) (E and F), body temperature (G), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (H), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (I) of sham or OVX rats ICV treated with vehicle or TUDCA (n = 7--8 animals per group).All data are expressed as mean ± SEM.^∗^ and ^∗∗^p \< 0.05 and 0.01 versus sham vehicle or OVX vehicle. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (β-actin or α-tubulin). The bands for each picture always from come from the same gel, although they have been spliced for clarity.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

GRP78 in the VMH Decreases Body Weight and Improves the Metabolic Phenotype of OVX Rats through the SNS {#sec2.5}
-------------------------------------------------------------------------------------------------------

Our first set of data showed that central treatment with E2 decreased ER stress and augmented the hypothalamic protein levels of GRP78 ([Figure 1](#fig1){ref-type="fig"}G). This was of importance because this protein is a chaperone, located in the ER, that facilitates the protein folding upstream of the UPR and therefore decreases ER stress levels ([@bib10], [@bib9]). Thus, a gain of function experiment was undertaken using an adenovirus encoding GRP78 or control adenoviruses expressing GFP alone injected into the VMH of OVX rats and their sham controls. Infection efficiency in the VMH was assessed by expression of GFP (similarly to [Figure 3](#fig3){ref-type="fig"}A; data not shown), and by increased concentration of GRP78 in the VMH ([Figures 6](#fig6){ref-type="fig"}E and 6F). GRP78 adenoviruses into the VMH induced feeding-independent weight loss in OVX rats, but not in sham rats ([Figures 6](#fig6){ref-type="fig"}A--6D). That effect was linked to decreased ER stress in the VMH of OVX, but not sham, rats ([Figures 6](#fig6){ref-type="fig"}E and 6F), increased body temperature ([Figure 6](#fig6){ref-type="fig"}G), BAT temperature ([Figure 6](#fig6){ref-type="fig"}H), and augmented UCP1 protein levels in BAT ([Figure 6](#fig6){ref-type="fig"}I). Notably, central administration of GRP78 in the VMH reduced the hepatic lipid content of OVX rats ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 6Effect of GRP78 Overexpression in the VMH of OVX Rats on Energy Balance and BAT Thermogenesis(A--I) Body weight change (A and C), daily food intake (B and D), representative western blot autoradiographic images (left panel) and VMH protein levels of UPR (right panel) (E and F), body temperature (G), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (H), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (I) of sham or OVX rats stereotaxically treated in the VMH with adenoviruses encoding GFP or GRP78 (n = 7--18 animals per group).All data are expressed as mean ± SEM. ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05, 0.01, and 0.001 versus sham GFP or OVX GFP. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (β-actin or α-tubulin). The bands for each picture always come from the same gel, although they have been spliced for clarity.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Finally, we investigated whether regulation of BAT following administration of GRP78 adenoviral particles in the VMH of OVX rats was mediated by the SNS. Pharmacological inactivation of β3-AR by SC administration of the specific antagonist, SR59230A ([@bib19], [@bib24], [@bib4], [@bib6], [@bib26], [@bib50]), prevented the effect on body weight associated with central administration of GRP78 viruses ([Figure 7](#fig7){ref-type="fig"}A) without affecting feeding ([Figure 7](#fig7){ref-type="fig"}B). Consistently, the treatment with SR59230A blunted the GRP78-induced increase in body temperature ([Figure 7](#fig7){ref-type="fig"}C), BAT temperature ([Figure 7](#fig7){ref-type="fig"}D), and UCP1 protein levels in the BAT ([Figure 7](#fig7){ref-type="fig"}E). Overall, this evidence demonstrates that E2-induced decrease of ER stress in the VMH is an important modulator of energy balance by controlling BAT thermogenesis.Figure 7Effect of β3-AR Antagonism on GRP78-Induced BAT Thermogenesis in OVX Rats(A--E) Body weight change (A), daily food intake (B), body temperature (C), representative infrared thermal images (left panel) and temperature of BAT area (right panel) (D), and representative western blot autoradiographic images (left panel) and protein levels of UCP1 in the BAT (right panel) (E) of OVX rats stereotaxically treated in the VMH with adenoviruses encoding GFP or GRP78 and subcutaneously treated with vehicle or the β~3~ adrenoceptor antagonist SR59230A (n = 7--19 animals per group).All data are expressed as mean ± SEM. ^∗∗^ and ^∗∗∗^p \< 0.01 and 0.001 versus OVX GFP vehicle; \# and \#\# p \< 0.05 and 0.01 versus OVX GRP78 vehicle. For the western blot analyses, representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (α-tubulin). The bands for each picture always come from the same gel, although they have been spliced for clarity.

Discussion {#sec3}
==========

This study identifies a link between the effects of E2 on hypothalamic ceramide-induced lipotoxicity and ER stress with BAT thermogenesis. We demonstrate that central E2 replacement restored hypothalamic ceramide levels and ER stress in OVX female rats. Of note, pharmacological or genetic blockade of ceramide synthesis and relief of ER stress recapitulate the effects of E2, namely increased BAT thermogenesis, weight loss, and reduced hepatic lipids.

Conditions of estrogen deficiency, such as ovariectomy or menopause, are associated with a positive energy balance, as result of hyperphagia and decreased energy expenditure, leading to enhanced adiposity ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]), hepatic lipid accumulation, and steatosis ([@bib39], [@bib60], [@bib40]) in animal models and humans. Peripheral and central estrogen replacement therapy reverts this phenotype both in women and in female rodents ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]). Recent evidence indicates that AMP-activated protein kinase (AMPK) in the VMH mediates the central effect of E2 on BAT thermogenesis through the SNS ([@bib24], [@bib25]). Considering the key role of AMPK on fatty acid metabolism ([@bib14], [@bib15], [@bib20]), this evidence directly links the central effects of estrogens with hypothalamic lipids. However, despite recent data showing sexual dimorphism in brain fatty acid content ([@bib45]) and even though peripheral E2 treatment reduces serum ceramide levels in OVX rats ([@bib58]), whether complex lipids metabolism is involved in the central actions of E2 remains unclear. This is relevant, because the hormonal regulation of lipid metabolism usually shows tissue-specific effects ([@bib19], [@bib26]). In this sense, we have recently reported that thyroid hormones (THs) modulate ceramide metabolism in an opposite fashion within different brain areas, such as the hypothalamus and the cerebral cortex ([@bib26]). Therefore, the fact that systemic E2 decreased serum ceramide levels ([@bib58]) did not imply a similar hypothalamic effect.

Compelling evidence indicates that hypothalamic ceramide-induced lipotoxicity is a pathological mechanism leading to obesity by suppressing BAT thermogenesis ([@bib4], [@bib6]). Importantly, pharmacological or genetic targeting of this pathway, causing reduced ceramide concentration and/or decreased ER stress ameliorates obesity ([@bib4], [@bib6]). However, it remains totally unknown whether fluctuations in ceramide levels and/or ER stress reflect brain changes associated with, for example, neuronal and/or glial metabolic activity ([@bib41], [@bib42], [@bib21]), or whether they might respond to or integrate nutritional and hormonal cues from the periphery ([@bib20]). Supporting this latter idea, several endocrine signals, such as THs ([@bib19], [@bib1], [@bib26], [@bib27]), leptin ([@bib63], [@bib54]), bone-morphogenetic protein 8B (BMP8B) ([@bib62], [@bib28]), glucagon-like peptide 1 (GLP-1) ([@bib2]), and, importantly, E2 ([@bib24], [@bib25]), have been shown to regulate hypothalamic fatty acid metabolism to modulate energy balance.

Thus, we hypothesized that E2-induced actions on energy balance could be mediated by modulation of hypothalamic ceramides and ER stress. Our data showed that central treatment with E2 induced a negative energy balance in OVX rats, associated with a reduction of hypothalamic ceramide-induced lipotoxicity and ER stress. Of note, central pharmacological inhibition of ceramide synthesis by using the SPTLC inhibitor myriocin suppressed hypothalamic ER stress and fully recapitulated the effects of E2 on energy balance. Next, we aimed to further investigate the specific hypothalamic nuclei where those actions take place. It is known that the VMH plays a major role in the modulation of BAT thermogenesis ([@bib33], [@bib5]) and that ERα is the site of action for E2 in the VMH to drive the modulation of BAT thermogenic function ([@bib35], [@bib64], [@bib24], [@bib25]). Therefore, following a genetic strategy we silenced SPTLC1 expression in the VMH of OVX obese rats. Specific downregulation of SPTLC exclusively in the VMH ameliorated ER stress and obesity and improved the metabolic health of OVX rats, including a reduction in hepatic lipid content. Overall, these data suggest that central E2 induces a negative energy balance by diminishing ceramide-induced lipotoxicity and ER stress, a hypothesis that was proven by treating OVX rats centrally with the chemical chaperone TUDCA or by genetically overexpressing the chaperone GRP78 within the VMH. Importantly, all the above effects were reversed by pharmacological blockage of β3-AR, therefore suggesting that VMH changes in ceramide signaling and hypothalamic ER stress induced by E2 to increase thermogenesis are conveyed via the sympathetic outflow to BAT.

In summary, in this study we demonstrate that E2 promotes an amelioration of ceramide-induced lipotoxicity and ER stress, specifically in the VMH. This action leads to increased BAT thermogenesis through the activation of sympathetic β3-AR signaling, an action that is associated with feeding-independent weight loss and reduced hepatic steatosis, as well as with a substantial attenuation (or reversal) of some of the metabolic hallmarks of OVX and menopause, namely, body weight gain, and hepatic steatosis. This evidence is of relevance because proper understanding of gender differences in the regulation of energy balance and how their impairment may lead to obesity have capital importance in the identification (and design) of targets for drug development ([@bib30], [@bib31], [@bib38], [@bib29], [@bib34], [@bib17]). In this context, our data provide insights into the physiological regulation of energy balance and its perturbation in estrogen-deficient states and suggest that the ceramide metabolism and ER stress may be a potential therapeutic target for the treatment of obesity associated with conditions of estrogen deficiency.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Contact for reagent and resource sharing {#sec4.2}
----------------------------------------

Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Miguel López (<m.lopez@usc.es>).

Experimental model and subject details {#sec4.3}
--------------------------------------

### Animals and housing conditions {#sec4.3.1}

Adult female Sprague-Dawley rats (250--300 g; *Animalario General USC*; Santiago de Compostela, Spain) were used for the experiments. The experiments were performed in agreement with the *International Law on Animal Experimentation* and were approved by the *USC Ethical Committee (Project ID 15010/14/006).* The animals were housed with an artificial 12-hour light (8:00 to 20:00)/12-hour dark cycle, under controlled temperature and humidity conditions and allowed to free access to standard laboratory chow and tap water. For all the procedures, the animals were caged individually, but for OVX recovery time the rats were housed in groups (4 rats/cage). During this post-operative recovery period the animals became accustomed to the handling procedure under non-stressful conditions.

Method details {#sec4.4}
--------------

### Ovariectomy {#sec4.4.1}

Rats were bilaterally ovariectomized (OVX) or Sham-operated as described previously ([@bib24], [@bib25]). Briefly, under ketamine--xylazine anesthesia (50 mg/kg, intraperitoneal, IP) both flanks were shaved, and rats were placed on their left flank. Then, an incision was made in the right flank skin and muscle layers. The ovary was then carefully pulled out. The distal part of uterine horn was ligated with surgical suture and then the ovary was removed after making a dissection between the suture and the ovary. After returning the horn into the abdominal cavity, the wound was closed suturing the muscle layer with surgical silk and applying surgical staples to the skin. The same procedure was applied to remove the left ovary. Sham surgeries were also performed, in which each ovary was exposed but not tied or dissected. All treatments (central or peripheral) on OVX rats were carried out two weeks after surgery to ensure a total washout of ovarian hormones, as previously reported ([@bib24], [@bib25]).

### Central and peripheral treatments {#sec4.4.2}

For the central estradiol experiments, intracerebroventricular (ICV) cannulae were stereotaxically implanted under ketamine/xylazine anesthesia, as previously described using the following coordinates 1.6 mm lateral to bregma, 0.6 mm posterior, 4.5 mm deep ([@bib18], [@bib19], [@bib62], [@bib23], [@bib24], [@bib25], [@bib4], [@bib6], [@bib28], [@bib26], [@bib50]). Animals were individually housed and used for experimentation four days later. Then, rats were subjected to a protocol of daily ICV injections of estradiol (17 β-estradiol; 1 nmol dissolved in 5 μL of saline containing 10% of DMSO; *Sigma;* St Louis, MO, USA) or vehicle (5 μL of saline containing 10% of DMSO; control rats) using a 22-gauge needle (*Hamilton;* Reno, NV, USA) through the inserted cannulae at 8:00 and 20:00 for 6 days ([@bib24], [@bib25]).

For the central treatment with myriocin or tauroursodeoxycholic acid (TUDCA), ICV cannulae were stereotaxically implanted under ketamine/xylazine anesthesia, as previously described and a catheter tube was connected from the cannulae to an osmotic minipump flow moderator (*model 2001*; *Alzet Osmotic Pumps*; Palo Alto, CA, USA) ([@bib28], [@bib6]), during the same surgery procedure. The minipump was inserted in a subcutaneous pocket on the dorsal surface of the animal, created using blunt dissection. The incision was closed. The rats were then infused with the serine palmitoyltransferase inhibitor, myriocin (4 μg/day dissolved in saline containing 1/3 of DMSO; *Sigma*; St Louis, MO, USA) or the chemical chaperone TUDCA (10 μg/day dissolved in PBS; *Calbiochem, Billerica*; MA, USA) or their respective vehicle (saline containing 1/3 of DMSO or PBS; control rats) for 6 days. The selection of these doses was based on previous reports ([@bib44], [@bib6]). Finally, the β3-AR specific antagonist SR59230A (\[3-(2ethylphenoxy)-1-\[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino\]-2S-2-propanol-oxalate\] (3 mg/Kg/day dissolved in DMSO; *Tocris Bioscience;* Bristol, UK) ([@bib19], [@bib24], [@bib4], [@bib6], [@bib26], [@bib50]) was administrated subcutaneously twice a day at the onset of the cycles at 8:00 and 20:00, starting 2 days before the first ICV and stereotactic injections.

### Stereotaxic microinjection of adenoviral vectors {#sec4.4.3}

Rats were placed in a stereotaxic frame (*David Kopf Instruments*; Tujunga, CA, USA) under ketamine/xylazine anesthesia. The VMH was targeted bilaterally using a 25-gauge needle (*Hamilton;* Reno, NV, USA). The injections were directed to the following stereotaxic coordinates: 2.4/3.2 mm posterior to the bregma (two injections were performed in each VMH), ± 0.6 mm lateral to midline and 10.1 mm ventral, as previously reported ([@bib18], [@bib19], [@bib62], [@bib23], [@bib24], [@bib25], [@bib4], [@bib6], [@bib28], [@bib26], [@bib27], [@bib50]). Adenoviral vectors (*Viraquest;* North Liberty, IA, USA) containing green fluorescence protein (GFP, used as control), GRP78 (at 10^12^ pts/mL), short hairpin serine palmitoyltransferase long chain subunit 1 (shSPTLC1, at 1.1x10^12^ pts/mL) were delivered at a rate of 200 nL/min for 5 min (1 μL/injection site) as previously reported ([@bib18], [@bib19], [@bib62], [@bib23], [@bib24], [@bib25], [@bib4], [@bib6], [@bib28], [@bib26], [@bib27], [@bib50]).

### Temperature measurements {#sec4.4.4}

Body temperature was recorded twice at the end of the treatments with a rectal probe connected to a digital thermometer (*BAT-12: Microprobe-Thermometer; Physitemp*; NJ, US). Skin temperature surrounding BAT was recorded with an infrared camera (*B335:Compact-Infrared-Thermal-Imaging-Camera; FLIR;* West Malling, Kent, UK) and analyzed with a specific software package (*FLIR-Tools-Software; FLIR;* West Malling, Kent, UK) ([@bib62], [@bib23], [@bib24], [@bib25], [@bib4], [@bib6], [@bib28], [@bib26], [@bib50]).

### Calorimetric system and nuclear magnetic resonance {#sec4.4.5}

Animals were analyzed for EE using a calorimetric system (*LabMaster; TSE Systems*; Bad Homburg, Germany). Animals were placed in a temperature-controlled (24°C) box through which air was pumped. After calibrating the system with the reference gases (20.9% O~2~, 0.05% CO~2~ and 79.05% N~2~), the metabolic rate was measured for 3 days, as previously shown ([@bib12], [@bib23], [@bib24], [@bib28], [@bib26], [@bib50]). EE were recorded every 30 min. Animals were placed for adaptation for 1 week before starting the measurements. For the measurement of body composition, we used nuclear magnetic resonance (NMR) (*Whole Body Composition Analyzer; EchoMRI*; Houston, TX) ([@bib12], [@bib23], [@bib24], [@bib28], [@bib26], [@bib50]). Animals do not need to be anesthetized neither other special preparation before measurement. They are placed in a holder of custom-defined size during the measurement (measuring time: 0.5-3.2 min). Two measurements were done twice for animal 72 h apart.

### Sample processing {#sec4.4.6}

Rats were killed by cervical dislocation and decapitation. From each animal, the MBH, VMH, liver and the interscapular BAT were collected for western blotting and Oil Red O staining and immediately homogenized on ice to preserve phosphorylated protein levels. Those samples and the serum were stored at −80°C until further processing. Dissection of the VMH was performed by micro-punch procedure under the microscope, as previously described ([@bib19], [@bib62], [@bib4], [@bib6], [@bib24], [@bib28], [@bib26], [@bib50]).

### Ceramide quantification {#sec4.4.7}

Ceramide analysis reported in this manuscript were performed in two different laboratories and according to the next methods. In the first one, ceramides were extracted and analyzed using liquid chromatography-mass spectrometer consisted of a *Waters* Acquity UPLC System connected to a *Waters* LCT Premier Orthogonal Accelerated Time of Flight Mass Spectrometer (*Waters*; Millford, MA, USA), operated in positive electrospray ionization mode. Full scan spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce data points each 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray by the LockSpray interference. The analytical column was a 100 mmL 2.1 mm i.d., 1.7 mm C8 Acquity UPLC BEH (*Waters*; Millford, MA, USA). The two mobile phases were phase A: methanol; phase B: water, both contained 0.2% formic acid (v/v) and 2 mM ammonium formate. A linear gradient was programmed (0.0 min: 20% B; 3 min: 10% B; 6 min: 10% B; 15min: 1% B; 18 min: 1% B; 20 min: 20% B; 22 min: 20% B). The flow rate was 0.3 mL/min. The column was held at 30°C. Quantification was carried out using the extracted ion chromatogram of each compound, using 50 mDa windows. The linear dynamic range was determined by injecting standard mixtures. Positive identification of compounds was based on the accurate mass measurement with an error \< 5 ppm and its LC retention time, compared to that of a standard (±2%). Concentrations were measured by multiple reaction monitoring experiments using N-lauroyl-D-erythro-sphingosine (C12-ceramide) and N-Heptadecanoyl-D-erytro-Sphingosine (C17-ceramide) as internal standards and using as patrons N-Palmitoyl-D-erytro-sphingosine (C16-ceramide), N-Stearoyl-D-erytro-sphingosine (C18-ceramide), N-lignoceroyl-D-erythro-sphingosine (C24-ceramide) and N-nervonoyl-D-erythro-sphingosine (C24:1-ceramide) (*Avanti Polar Lipids*; Alabaster, AL, USA). The ceramide analyses from [Figure 1](#fig1){ref-type="fig"}K were performed in the *Research Unit on Bioactive Molecules* (*RUBAM*) of the Institut de Química Avançada de Catalunya (IQAC-CSIC) according to this method.

In the second one, total lipid species were extracted according to the method of [@bib8]. Ceramide lipid species were enriched in the lower phase (organic phase) and analyzed using an untargeted lipidomic approach by liquid chromatography coupled with high-resolution mass spectrometry (LC--HRMS) as described by [@bib51]. The ceramide analyses from [Figure 1](#fig1){ref-type="fig"}F were performed in the *Unité de Biologie Fonctionnelle et Adaptative* (Univertsité Paris Diderot) according to this method.

### Histological analyses {#sec4.4.8}

Hepatic lipid content was analyzed by Oil Red O staining, as previously shown ([@bib49], [@bib4], [@bib6], [@bib13], [@bib43], [@bib26]). Hepatic frozen sections were cut (8 μm) and fixed in 10% buffered formaldehyde. Sections were stained in filtered Oil Red O (*Sigma*; St. Louis, MO, USA), washed in distilled water, counterstained with Harris hematoxylin (*Bio-Optica*; Milan, Italy) and washed in distilled water again. Sections were mounted in aqueous mounting medium (*Bio-Optica;* Milan, Italy). Images were taken with a digital camera *Olympus XC50* (*Olympus Corporation*; Tokyo, Japan) at 20X. Digital images of liver were quantified with *ImageJ Software* (*National Institutes of Health*; USA). Direct detection of GFP fluorescence was performed after perfusion of the animals; on 40 μm brain sections. Images were taken with a fluorescence microscope *Olympus IX51*, as previously shown ([@bib6], [@bib50]).

### Western blotting {#sec4.4.9}

Protein lysates from hypothalamus (MBH or VMH) and BAT were homogenized in lysis buffer (consisting of a mix of 0.05 M Tris-HCl, 0.01 M EGTA, 0.001 M EDTA, 0.016 M Triton X-100, 0.001 M sodium orthovanadate, 0.05 M sodium fluoride, 0.01 M sodium pyrophosphate and 0.25 M sucrose, made up with distilled water and adjusted to 7.5 pH; all of them from *Sigma*; St. Louis, MO, USA) and freshly added protease inhibitor cocktail tablets (*Roche Diagnostics*; Indianapolis, IN, USA). The protein concentration was determined by the *Bradford Method* (Protein assay dye concentrate, *Bio-Rad Laboratories*; Hercules, CA, USA), and the total protein content of the tissues was calculated. The protein lysates were subjected to SDS-PAGE, electrotransferred to polyvinylidene difluoride membranes (PVDF; *Millipore*; Billerica, MA, USA) with a semidry blotter and probed with antibodies against GRP78 (*Cell Signaling*; Danvers; MA, USA); ATF6α, CHOP, peIF2α (Ser52), pPERK (Thr981) (*Santa Cruz*; Santa Cruz, CA,USC); pIREα (Ser724), SPTLC1, SPTLC2, UCP1 (*Abcam*; Cambridge, UK); α-tubulin or β-actin (*Sigma*; St. Louis, MO, USA) as described ([@bib19], [@bib57], [@bib24], [@bib4], [@bib26], [@bib50]). Each membrane was then incubated with the corresponding secondary antibody: anti-mouse or anti-rabbit (all of them from *DAKO*; Glostrup, Denmark). The membranes were exposed to an X-ray film (*Fujifilm*; Tokyo, Japan) and developed using developer (*Developer G150; AGFA HealthCare*: Mortsel, Belgium) and Fixator (*Manual Fixing G354; AGFA HealthCare*: Mortsel, Belgium).

Autoradiographic films were scanned and the bands signal was quantified by densitometry using *ImageJ-1.33 software* (*NIH*; Bethesda, MD, USA). Values were expressed in relation to β-actin (hypothalamus) or α-tubulin (BAT). Representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed for clarity, although each band of each protein was always corrected by its own internal control band (β-actin or α-tubulin). In all the Figures showing images of gels, all the bands for each picture come always from the same gel, although they may be spliced for clarity.

Quantification and statistical analysis {#sec4.5}
---------------------------------------

*ImageJ-1.33 software* (*NIH*; Bethesda, MD, USA) was used to process western blot analyses and liver histologic images ([@bib19], [@bib57], [@bib24], [@bib4], [@bib26], [@bib27], [@bib50]). *FLIR-Tools-Software; FLIR;* West Malling, Kent, UK) was used to process the thermal images ([@bib62], [@bib23], [@bib4], [@bib6], [@bib24], [@bib25], [@bib28], [@bib26], [@bib50]). Statistical analysis was conducted using *GraphPad Prism 6 Software* (*GraphPad Software, Inc.*; La Jolla, CA, USA). Data are expressed as mean ± SEM. Protein data were expressed in relation (%) to control (Sham or OVX, vehicle or GFP treated) rats. Error bars represent SEM. Statistical significance was determined by Student's t test (when two groups were compared) or ANOVA (when more than two groups were compared) followed by post hoc Bonferroni test. p \< 0.05 was considered significant. The number of animals used in each experimental setting and analysis are specified in each figure legend.
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